Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engert, A
Right arrow Articles by Diehl, V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engert, A
Right arrow Articles by Diehl, V
Haematologica, Vol 91, Issue 4, 546-549
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial, Phase II

Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study

A Engert, H Bredenfeld, H Dohner, AD Ho, N Schmitz, D Berger, P Bacon, T Skacel, V Easton, and V Diehl

Department I of Internal Medicine, University of Cologne, Cologne, Germany. a.engert@uni-koeln.de

The primary endpoint of this feasibility study was to determine whether pegfilgrastim support could enable the delivery of the full dose of BEACOPP chemotherapy every 14 days on schedule. Forty-one patients with high-risk Hodgkin's lymphoma were randomized to receive pegfilgrastim (6 mg) on day 4 or 8 of each cycle. Eighty-one percent of cycles administered were delivered at full dose and on schedule (FDOS). Response was retrospectively assessed in 27 patients at 6 months; 23 of these 27 patients (85%) achieved a complete response and one (4%) achieved a partial response. Toxicities were mostly moderate in intensity. These results support the feasibility of delivering full dose, on schedule BEACOPP-14, chemotherapy with pegfilgrastim support.


This article has been cited by other articles:


Home page
 ASH Education BookHome page
S. J. Horning
Risk, Cure and Complications in Advanced Hodgkin Disease
Hematology, January 1, 2007; 2007(1): 197 - 203.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.